HARRIS ERIK 1780113 Data last updated 2024-05-14 07:02:16 -0500 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-05 | 2023-06-01 | 2023-06-01 | 4 | Harris Erik | DIRECTOR | acq | 4216.0 | 38.03 | 0.31 | 0.0 | Direct | Common Stock | DENALI THERAPEUTICS INC. | code A | 11085.0 | 136.89 (DNLI) |
| 2023-06-21 | 2023-06-19 | 2023-06-19 | 4 | Harris Erik | EVP & CHIEF COMMERCIAL OFFICER | dsp | 305.0 | 0.53 | 0.04 | 48.2 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code S | 57281.0 | 70.81 (RARE) |
| 2023-09-06 | 2023-09-05 | 2023-09-05 | 4 | Harris Erik | EVP & CHIEF COMMERCIAL OFFICER | dsp | 6000.0 | 10.47 | 0.84 | 37.96 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code S | 51281.0 | 71.49 (RARE) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Harris Erik | EVP & CHIEF COMMERCIAL OFFICER | acq | 20357.0 | 28.42 | 2.48 | 0.0 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code A | 71638.0
|
82.11 (RARE) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Harris Erik | EVP & CHIEF COMMERCIAL OFFICER | dsp | 4768.0 | 6.63 | 0.58 | 53.76 | Direct | Common Stock | ULTRAGENYX PHARMACEUTICAL INC. | code S | 67163.0 | 82.11 (RARE) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-06-05 | 2023-06-01 | 2023-06-01 | 4 | Harris Erik | DIRECTOR | acq | 12649.0 | 100.0 | 0.92 | 30.92 | Direct | Stock Option (Right To Buy) | DENALI THERAPEUTICS INC. | code A | 12649.0 | 136.89 (DNLI) |
| 2024-03-05 | 2024-03-01 | 2024-03-01 | 4 | Harris Erik | EVP & CHIEF COMMERCIAL OFFICER | acq | 34200.0 | 100.0 | 4.16 | 53.69 | Direct | Stock Option (Right To Buy) | ULTRAGENYX PHARMACEUTICAL INC. | code A | 34200.0 | 82.11 (RARE) |
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)